EyePoint Pharmaceuticals Files 8-K on Financials
Ticker: EYPT · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on Aug 7th covering financials. Check it for performance updates.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting on its Results of Operations and Financial Condition, and submitting Financial Statements and Exhibits. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing provides an update on EyePoint Pharmaceuticals' financial condition and operational results, which is crucial information for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- August 07, 2024 (date) — Date of earliest event reported
- Watertown, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on EyePoint Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, and to submit Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on August 7, 2024.
What are the former names of EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
Where are EyePoint Pharmaceuticals, Inc.'s principal executive offices located?
EyePoint Pharmaceuticals, Inc.'s principal executive offices are located at 480 Pleasant Street, Suite B300, Watertown, Massachusetts, 02472.
What is the Commission File Number for EyePoint Pharmaceuticals, Inc.?
The Commission File Number for EyePoint Pharmaceuticals, Inc. is 000-51122.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-07 07:00:09
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20240807.htm (8-K) — 38KB
- eypt-ex99_1.htm (EX-99.1) — 34KB
- img96707757_0.jpg (GRAPHIC) — 5KB
- img96707757_1.jpg (GRAPHIC) — 92KB
- img96707757_2.jpg (GRAPHIC) — 104KB
- 0000950170-24-092262.txt ( ) — 465KB
- eypt-20240807.xsd (EX-101.SCH) — 23KB
- eypt-20240807_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 7, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc., dated August 7, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: August 7, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer